News of Note: mRNA vaccine for melanoma

Key Takeaways:

• Melanoma is a very aggressive form of skin cancer.
• Ongoing clinical trials are showing promise for the approval of an mRNA vaccine that can stop the recurrence of cancer in patients with melanoma.
• If the vaccine receives FDA approval as anticipated, it has the potential to be practice changing for the treatment of many types of cancer.

In August, Moderna and Merck reported positive results from a large phase III clinical trial studying an individualized mRNA-based therapy for patients with high-risk melanoma.

These results are exciting not only because of their potential impact on melanoma treatment, but also because this approach represents a new way of treating cancer, creating a therapy specifically tailored to the unique characteristics of an individual patient’s tumor.

In this blog, we’re going to talk about melanoma, the vaccine, and what this breakthrough could mean for cancer care.

What is melanoma?

Melanoma is a cancer that develops from melanocytes, the pigment-producing cells found primarily in the skin. Melanocytes produce melanin, which helps protect the skin from damage caused by UV radiation.

When melanoma occurs, it is in a very aggressive cancer that can spread to our lymph nodes or to distant organs in the body.

This type of skin cancer is less common than other types of skin cancer, such as squamous cell carcinomas or basal cell carcinomas. 

Fortunately, when melanoma is found early, surgery can often cure it. The risk of recurrence increases as melanoma becomes thicker or spreads to lymph nodes or other parts of the body.

What is the mRNA vaccine, and how is it preventing the spread and recurrence of melanoma?

The treatment is called intismeran autogene, also known as V940. It is an individualized neo-antigen therapy that uses mRNA technology.

Although it is often referred to as a cancer “vaccine,” it is very different from vaccines we routinely receive to prevent infections, such as measles or influenza. This treatment is not given to healthy people to prevent melanoma from developing. It is being studied in people who have already had melanoma.

After a patient’s melanoma is surgically removed, the tumor is sequenced to identify mutations that produce abnormal proteins, or neo-antigens, that are unique to that patient’s cancer. A personalized mRNA therapy is then created containing instructions for selected neo-antigens from that tumor.

The goal is to teach the patient’s immune system to recognize those tumor-specific targets so that immune cells can identify and destroy melanoma cells that may remain in the body after surgery. 

The vaccine is being studied in combination with pembrolizumab, an immune checkpoint inhibitor that helps the immune system maintain its anti-tumor response.

Do you have to have a certain stage of melanoma to qualify for the mRNA vaccine?

Right now, intismeran autogene remains investigational and is not yet an FDA-approved treatment for melanoma.

The initial randomized phase IIb study, KEYNOTE-942, evaluated the personalized mRNA therapy plus pembrolizumab in patients with completely resected, high-risk stage III or IV melanoma.

The larger phase III trial, INTerpath-001, expanded the population to patients with completely resected stage IIB, IIC, III, or IV cutaneous melanoma who were at significant risk for recurrence.

Exactly which patients may ultimately be eligible for this treatment will depend on the complete phase III results and, if the therapy is approved, the indication authorized by the FDA.

What kind of success are we seeing with it?

In the phase IIB KEYNOTE-942 trial, patients received either pembrolizumab alone or pembrolizumab together with the individualized mRNA therapy. 

With approximately five years of follow-up, the combination reduced the relative risk of recurrence or death by 49 percent compared with pembrolizumab alone.

We know in August 2026 that Moderna and Merck announced the much larger phase III INTerpath-001 trial was positive and have already met the primary endpoint of recurrence-free survival and distant metastasis-free survival endpoint as well. 

However, we do not know the actual numbers of that positive result.

Will it eventually be used as a preventive strategy for melanoma?

That is a different type of question because that is asking whether we can prevent melanoma from ever occurring.

The way to prevent melanoma from occurring is to prevent sunburn and protect the skin from UV exposure by using sunscreen, clothing, hats and avoiding tanning beds.

This therapy does not prevent someone from developing melanoma in the first place.

What makes this treatment particularly interesting is its individualized nature. We are not simply giving the same vaccine to every person with melanoma. Each treatment is created using information obtained from that individual patient’s tumor.

The tumor is sequenced, tumor-specific neo-antigens are identified, and an mRNA therapy is manufactured to target selected neoantigens from that person’s cancer. 

Another patient will have a different tumor with different mutations and therefore receives a differently designed therapy.

Does this vaccine have the potential to usher in similar vaccines for other types of cancers?

The answer is yes because this is not a drug just looking at all melanomas. The underlying concept is not specific to melanoma. 

Many cancers contain mutations that create neo-antigens that distinguish cancer cells from normal cells. In principle, those neo-antigens can be identified and used to create an individualized therapy designed to direct the immune system against that person’s tumor.

This strategy is already being studied in several other cancers, including lung cancer, renal cell carcinoma, and bladder cancer.

Whether it will produce the same degree of benefit in those cancers remains unknown, and that is exactly what ongoing clinical trials are trying to determine.

What’s the most important takeaway right now?

The most important point is that this is a promising new treatment strategy, but it remains investigational today.

We now know that the phase III melanoma trial met its major efficacy endpoints, which is an important milestone. 

However, we still need to see the complete data to understand the magnitude and durability of the benefit, the safety profile, and which patients are most likely to benefit.

This also does not replace the fundamentals of melanoma care. Finding melanoma early remains extremely important, and surgery continues to be the primary curative treatment for localized melanoma.

For patients whose melanoma carries a higher risk of returning after surgery, however, individualized mRNA therapy could potentially add a new approach to adjuvant treatment.

Promise for the future

This drug may become practice-changing, but we need to wait for the results of the phase III double-blinded trial. 

Personalized neo-antigen therapy takes that concept a step further by using the molecular characteristics of an individual patient’s tumor to create a treatment specifically for that patient.

If the phase III data confirm a meaningful clinical benefit and the therapy receives regulatory approval, this could represent an important advance in melanoma treatment and an early example of how individualized cancer vaccines may become part of cancer care in the future.